Triatomic Management LP Intellia Therapeutics, Inc. Transaction History

Triatomic Management LP

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 03, 2023	SELL	$33.3 - $44.82 $333,000 - $448,200	-10,000 Reduced 50.0%	10,000 $372,000
Q4 2022 Feb 13, 2023	BUY	$33.21 - $62.69 $664,200 - $1.25 Million	20,000 New	20,000 $697,000

336

96.1M

1.06M

863K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $684M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Triatomic Management LP, based on Form 13F filings with the SEC.

Stay updated on Triatomic Management LP with notifications on news.